There is a newer version of this record available.

Report Open Access

Statistical review of A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 by B. Cao et al

Gates, Simon; Emsley, Richard; Dahly, Darren


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">COVID-19</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">clinical trials</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">RCTs</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Lopinavir</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Ritonavir</subfield>
  </datafield>
  <controlfield tag="005">20200413062546.0</controlfield>
  <controlfield tag="001">3746512</controlfield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">NIHR Research Professor &amp; Professor of Medical Statistics and Trials Methodology, Department of Biostatistics and Health Informatics, King's College London, UK</subfield>
    <subfield code="a">Emsley, Richard</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Principal Statistician, HRB Clinical Research Facility - Cork. HRB Trials Methodology Research Network. Senior Lecturer in Patient Focused Research Methods, University College Cork School of Public Health</subfield>
    <subfield code="a">Dahly, Darren</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">148916</subfield>
    <subfield code="z">md5:c139dbcfe8d74902ab4682026f95e384</subfield>
    <subfield code="u">https://zenodo.org/record/3746512/files/Review_20_03_28_Cao.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2020-04-09</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-covid-19-tx-rct-stats-review</subfield>
    <subfield code="p">user-zenodo</subfield>
    <subfield code="o">oai:zenodo.org:3746512</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Professor of Biostatistics and Clinical Trials, Cancer Research UK Clinical Trials Unit, University of Birmingham, UK</subfield>
    <subfield code="a">Gates, Simon</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Statistical review of A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 by B. Cao et al</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-covid-19-tx-rct-stats-review</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-zenodo</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical&amp;nbsp; trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments,&amp;nbsp; independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews&amp;nbsp; focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). Here we review &lt;em&gt;A Trial of Lopinavir&amp;ndash;Ritonavir in Adults Hospitalized with Severe Covid-19&lt;/em&gt;, by B.Cao &lt;em&gt;et al&lt;/em&gt;, published in the New England Journal of Medicine on 18 March 2020. This was one of the first randomised controlled trials of treatments for COVID-19 to be published, and the first in a high-profile medical journal.&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.3746511</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.3746512</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">report</subfield>
  </datafield>
</record>
1,318
885
views
downloads
All versions This version
Views 1,318997
Downloads 885567
Data volume 131.9 MB84.4 MB
Unique views 1,133886
Unique downloads 731521

Share

Cite as